Melanoma

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private…

6 months ago

OncoHost Named Top Precision Oncology Solution for 2025

BINYAMINA, Israel and CARY, N.C., July 30, 2025 /PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to…

6 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone

Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE)…

6 months ago

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to…

6 months ago

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that…

6 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company…

6 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of…

6 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered…

6 months ago

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while…

6 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Agreement covers contract development and manufacturing of lead compound PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio…

6 months ago